Alksne Lefa E
Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA.
Expert Opin Investig Drugs. 2002 Aug;11(8):1149-59. doi: 10.1517/13543784.11.8.1149.
Bacterial resistance to present day antibiotics has become a dangerous threat to public health. Consequently, the pharmaceutical industry must provide new agents and novel classes to combat bacterial disease and to stay a step ahead of the rapid evolution of bacterial resistance mechanisms. The need for novel antibacterials has resulted in a search for previously unexplored targets for chemotherapy, utilising the new techniques of genomics to identify them. Several targets currently under investigation are involved in the process of bacterial virulence. These targets are unique in that their inhibition, by definition, should interfere with the process of infection rather than with bacterial viability. If successful, virulence inhibition may represent a 'kinder, gentler' approach to chemotherapy in which the pathogen is disarmed rather than killed outright.
细菌对当今抗生素的耐药性已成为对公众健康的严重威胁。因此，制药行业必须提供新的药物和新型药物类别，以对抗细菌性疾病，并在细菌耐药机制的快速演变中保持领先一步。对新型抗菌药物的需求促使人们利用基因组学新技术寻找以前未被探索的化疗靶点。目前正在研究的几个靶点与细菌毒力过程有关。这些靶点的独特之处在于，根据定义，对它们的抑制应该干扰感染过程，而不是细菌的生存能力。如果成功，抑制毒力可能代表一种“更温和、更柔和”的化疗方法，即解除病原体的武装而不是直接杀死它。
